Two of our hit compounds, #5333 (also called SVI-5333) and #5338 (also called SVI-5338), had a significantly increased therapeutic window compared to WS6 and inhibited the malignant phenotype of neuroblastoma cells in vitro, which partly depended on PA2G4 and MYCN expression. The gene discussed is MYCN; the disease is neuroblastoma.